CER Daily Newsfeed

Value Viewpoint: December 13, 2024

(12/13, Kimberly Westrich, LinkedIn) comments “...One of the flaws is that ICER’s analysis fails to account for inflation when calculating the report’s headline estimate. If ICER adhered to basic standards for economic analysis and adjusted its findings for inflation using the CPI-U, the supposed $815 million ‘increase’ cited in this year’s report would instead become a $10 million decrease. However, relying on robust, evidence-based methods that better reflect real-world market dynamics wouldn’t generate the shock value or attention-grabbing headlines that ICER seems to prioritize.” Full

Why Developing An Evidence Generation Plan Early In The Asset Life Cycle Of Pharmaceutical Products Is Critical

(12/16, Nida Khan, Forbes.com) comments “...In today’s healthcare environment, some regulatory authorities are demanding more comprehensive and early data that go beyond the traditional efficacy and safety endpoints. Likewise, some payers are increasingly reluctant to approve reimbursement without compelling real-world evidence demonstrating the drug’s value over existing treatments. By developing an EGP during phase one, you can proactively plan to meet these evolving expectations, ensuring your asset is aligned with regulatory needs and prepared to demonstrate value to payers when it reaches the market.” Full

Assessing Provider Adoption Of Medicare Advanced Alternative Payment Models

(12/16, David Muhlestein, Health Affairs Forefront) comments “...There has been significant adoption of AAPMs over the past seven years, although much work remains to be done. To achieve its aggressive goals, CMS needs to significantly expand the number of providers who are participating in APMs. They can do this by continuing to develop targeted new advanced alternative payment models while also strongly incentivizing providers to join the existing models. Understanding how individual providers are participating in different models and how that varies by factors such as specialty and location will be key to help CMS direct its efforts in the most efficient way.” Full

UK: What is NICE’s Severity Modifier?

(12/16, NICE) comments “...In September 2024, NICE’s board found that the severity modifier is working as intended and that no change is required. The severity modifier is therefore unlikely to change or be adjusted in the near future. NICE’s board has agreed to continue monitor the impact of the severity modifier. As part of this work, it will commission additional research into what society’s preferences are in terms of valuing medicines that treat severe diseases.” Full